Welcome to our dedicated page for Elicio Therapeutics news (Ticker: ELTX), a resource for investors and traders seeking the latest updates and insights on Elicio Therapeutics stock.
Elicio Therapeutics reports developments as a clinical-stage biotechnology company developing cancer immunotherapies. Company news centers on its proprietary Amphiphile, or AMP, technology, the ELI-002 program, and immunotherapy work for mKRAS-positive cancers including pancreatic ductal adenocarcinoma, colorectal cancer, lung cancer, and other KRAS-driven tumors.
Recurring updates also include clinical and regulatory disclosures, operating and financial results, healthcare-conference presentations, shareholder voting and governance matters, capital-structure actions, and Nasdaq inducement stock option grants under the company’s 2024 Inducement Incentive Award Plan.
Elicio Therapeutics (Nasdaq: ELTX) reported second quarter 2026 results and clinical updates focused on its lead KRAS-targeted immunotherapy ELI-002 7P. Multiple complete responses were observed following ELI-002 7P treatment and subsequent checkpoint inhibition in metastatic mKRAS pancreatic cancer, supporting a planned Phase 1 combination study with a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor, anticipated to start in Q4 2026.
The Phase 2 AMPLIFY-7P adjuvant PDAC trial did not meet its primary endpoint, and Elicio is analyzing pre-specified subgroups to inform Phase 3 strategy. An investigator-initiated neoadjuvant Phase 1 trial led by Memorial Sloan Kettering has been activated. Elicio completed a $15 million July 2026 financing and raised $24.4 million year to date via its ATM, ending June 30 with $23.5 million in cash and cash equivalents and expecting runway into Q1 2027. Q2 2026 R&D was $6.8 million, G&A $3.6 million, and net loss $8.2 million, or $0.43 per share.
Elicio Therapeutics (Nasdaq: ELTX) announced activation of an investigator-initiated, randomized, open-label Phase 1 neoadjuvant trial (NCT07671339) of its AMP-based KRAS-targeted immunotherapy ELI-002 7P in resectable and borderline resectable KRAS-mutant pancreatic ductal adenocarcinoma (PDAC). The multi-center study, conducted by Memorial Sloan Kettering Cancer Center and funded by a partnership between The Lustgarten Foundation and Break Through Cancer, aims to enroll 20 patients.
Patients will receive ELI-002 7P with standard neoadjuvant chemotherapy mFOLFIRINOX, with or without the anti-PD1 checkpoint inhibitor tislelizumab, starting before surgery and continuing afterward. The study will collect tumor and blood samples to assess immune activation, tumor microenvironment changes and potential biomarkers to guide future trials. ELI-002 7P, covering seven common KRAS mutations present in about 25% of solid tumors, has previously been evaluated in the Phase 2 AMPLIFY-7P trial in high-risk mKRAS-positive pancreatic cancer, where overall survival data remained immature at the time of analysis. Elicio is also planning additional ELI-002 7P studies in metastatic and adjuvant PDAC and other mKRAS-positive cancers.
Elicio Therapeutics (Nasdaq: ELTX) closed a previously announced registered direct offering of 4,380,313 common shares, raising approximately $15 million in gross proceeds before fees.
The company plans to use funds to support Phase 1 development of ELI-002 7P in metastatic PDAC, advance its pipeline and platform, and for working capital and general corporate purposes.
Elicio Therapeutics (Nasdaq: ELTX) priced a registered direct offering of 4,380,313 common shares, led by two new institutional investors and a large existing shareholder. The deal is expected to raise about $15 million in gross proceeds, closing around July 6, 2026, subject to customary conditions.
According to Elicio, net proceeds plus existing cash will primarily fund planned Phase 1 development of ELI-002 7P in metastatic PDAC, its broader pipeline and platform, and general corporate purposes.
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotech developing immunotherapies for KRAS-driven cancers, has been added to the Russell 2000 and Russell 3000 indexes, effective after the U.S. market close on June 26, 2026, following the 2026 Russell reconstitution.
The company views this as a milestone that broadens visibility with institutional investors as it advances its ELI-002 7P program.
Elicio Therapeutics (Nasdaq: ELTX) reported three metastatic mKRAS pancreatic cancer patients who progressed on ELI-002 7P in Phase 2 AMPLIFY-7P and later achieved 100% confirmed complete radiographic and metabolic responses after nivolumab-based therapy, with CA19-9 normalization and persistent mKRAS-specific T cells.
According to Elicio, these preliminary observations support evaluating ELI-002 7P with checkpoint inhibition. Subject to funding, the company plans a Phase 1 first-line metastatic PDAC study using gemcitabine/nab-paclitaxel plus anti–PD-1, designed for rapid clinical activity assessment.
Elicio Therapeutics (Nasdaq: ELTX) reported Phase 2 AMPLIFY-7P results in adjuvant mKRAS-driven pancreatic cancer. The study did not meet its primary DFS endpoint in the intent-to-treat population. Post-hoc analyses showed improved DFS in R0 resected patients (HR 0.65, p=0.048) and strong mKRAS-specific T cell correlations (HR 0.22, p<0.0001). ELI-002 7P showed a favorable safety profile with no treatment-related discontinuations or deaths. Guided by these data, Elicio plans a Phase 3 trial focused on R0 patients with extended dosing, subject to financing. The company expects existing cash to fund operations into Q4 2026.
Elicio Therapeutics (Nasdaq: ELTX) reported preclinical data in Science Advances on its lymph node-targeted AMP-DNA adjuvant platform. Studies in mice and non-human primates showed robust, polyfunctional CD8+ and CD4+ T cell responses, durable immune memory for at least nine months, and high neutralizing antibody titers.
AMP-DNA outperformed clinical and commercial benchmark adjuvants, enabled precise lymph node delivery, and drove immune activation through TBK1/IFN-I signaling, expanding Elicio’s AMP immunomodulator portfolio alongside AMP-CpG (ELI-004) for potential next-generation oncology and infectious disease immunotherapies.
Elicio Therapeutics (Nasdaq: ELTX) reported Q1 2026 results and clinical updates. The Phase 2 AMPLIFY-7P primary disease-free survival analysis of ELI-002 7P in post-resection mKRAS PDAC is expected mid-2026, with fewer progressions and deaths than projected.
Q1 R&D was $6.8M, G&A $3.8M, net loss $11.8M ($0.65/share). Cash was $14.9M on March 31, plus $13.0M raised via ATM, supporting operations into Q4 2026.
Elicio Therapeutics (Nasdaq: ELTX) will present at the Bank of America Healthcare Conference in Las Vegas on May 14, 2026 at 12:20 PM ET.
Presenters include CEO Robert Connelly, CMO Christopher Haqq, CSO Pete DeMuth, and CSFO Preetam Shah. A live webcast and 90-day replay are available via the company’s Events page. 1×1 meetings are arranged through Bank of America representatives.